Femasys Inc. announced the appointment of Dov Elefant to chief financial officer (CFO), to be effective February 28, 2022. Mr. Elefant has 25 years of financial management experience at both public and private biopharmaceutical companies. Most recently, he was the vice president and CFO of Cellectar Biosciences.

Before that, Mr. Elefant served as CFO of Celsus Therapeutics until its acquisition of Swiss company, Volution Immuno Pharmaceuticals in 2015, when it was then renamed Akari Therapeutics Plc.